New antibody drug shows promise for tough eczema cases
NCT ID NCT06094179
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called BAT6026 in 33 adults with moderate to severe atopic dermatitis (eczema) that hasn't responded well to topical treatments. The drug is a monoclonal antibody given as an injection. The goal is to see if it is safe and can reduce eczema severity by at least 75% after 16 weeks. This early-phase trial will help determine the best dose for future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BAT6026 (a monoclonal antibody)
What this could lead to
If successful, this could point toward a new treatment option for people with moderate to severe atopic dermatitis that is not well controlled by current creams or ointments.
What could go wrong
This is an early-phase trial with only 33 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATITIS, ATOPIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jianzhong Zhang
Beijing, Beijing Municipality, China